Annovis Bio's Buntanetap Shows Promise in Alzheimer's Trial with Cognitive Gains
Annovis Bio has released new trial data for its Alzheimer's drug, buntanetap, which shows promising cognitive improvements in patients with mild to moderate Alzheimer's disease. The Phase 2/3 trial, involving 351 participants over 12 weeks, tested three doses of buntanetap against a placebo. Notably, patients in the early stages of the disease who tested positive for the biomarker pTau217 exhibited significant cognitive improvements. Unlike traditional Alzheimer's treatments that target a single toxic protein, buntanetap aims to block the production of multiple harmful proteins, potentially altering the disease's progression. The drug was well-tolerated across all doses, including among genetically vulnerable ApoE4 carriers, and did not require patients to stop existing medications. 
